WST West Pharmaceutical Services
- 385.730
- -4.470-1.15%
- 388.550
- +2.820+0.73%
West Pharmaceutical Services News
Buy Rating Affirmed for West Pharmaceutical Services on Robust Market Position and Growth Prospects
West Pharmaceutical Servs Analyst Ratings
Analysts Have Conflicting Sentiments on These Healthcare Companies: Bio-Rad Laboratories (BIO), Ultragenyx Pharmaceutical (RARE) and West Pharmaceutical Services (WST)
Keybanc Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $470
West Pharmaceutical Servs Analyst Ratings
Jefferies Upgrades West Pharmaceutical Services to Buy From Hold, Adjusts Price Target to $536 From $323
West Pharmaceutical Servs Analyst Ratings
Hold Rating on West Pharmaceutical Services Amid Balanced Growth Prospects and Expansion Investments
Stephens & Co. Maintains Overweight on West Pharmaceutical Servs, Lowers Price Target to $390
West Pharmaceutical Servs Analyst Ratings
Deutsche Bank Cuts West Pharmaceutical Services Price Target to $350 From $360, Maintains Hold Rating
West Pharmaceutical Stock (NYSE:WST): Analyst Reaffirms Buy Rating Post Q3 Results
West Pharmaceutical Services: A Buy Rating Despite Lowered Revenue Guidance – A Deep Dive Into Financial Performance and Market Positioning
Keybanc Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $440
West Pharmaceutical Servs Analyst Ratings
What 4 Analyst Ratings Have To Say About West Pharmaceutical Servs
Keybanc Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $415
West Pharmaceutical Servs Analyst Ratings
Keybanc Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $385
West Pharmaceutical Servs Analyst Ratings
Analysis
Price Target
No Data
